Ongoing legislative developments and the latest experiences with implementing alternative payment mechanisms are just some of the reasons Clifford Goodman, PhD, senior vice president and director at the Center for Comparative Effectiveness Research at the Lewin Group, is looking forward to the fall meeting of the ACO & Emerging Healthcare Delivery Coalition.
Ongoing legislative developments and the latest experiences with implementing alternative payment mechanisms are just some of the reasons Clifford Goodman, PhD, senior vice president and director at the Center for Comparative Effectiveness Research at the Lewin Group, is looking forward to the fall meeting of the ACO & Emerging Healthcare Delivery Coalition.
Transcript (slightly modified)
Why should someone attend the fall meeting of the ACO & Emerging Healthcare Delivery Coalition, being held October 26-27 in Nashville, Tennessee?
Thinking about the fall meeting in Nashville, I’m already looking forward to that because of a few things. One is that by then, we’re going to see a lot more of how the healthcare legislation is going to be playing out. What really will have happened to the Affordable Care Act? Will there really be a new AHCA [American Health Care Act] in place? Those contextual trends are going to be very important for understanding where we go next with the ACO Coalition. That’s a very important thing.
Also, I see a trend, or I should say kind of an ongoing continuous development, of shared learning among our people that do attend this meeting on an ongoing basis. We continue to develop, learn from, refine, and then continue to implement these different sort of models, value-based models, for really providing alternative payment mechanisms for accountable care organizations and others to better serve our patient populations.
It’s the changes in the political environment, certainly advances in sciences and the state-of-the-art, and the ongoing exchange of on-the-ground experience that will make an event like that really successful.
Key Indicators of Myasthenia Gravis Disease Progression Reduced With Efgartigimod
April 18th 2025Research presented at the recent annual meeting of the Academy of Managed Care Pharmacy highlights outcomes among patients who have anti-acetylcholine receptor antibody-positive myasthenia gravis that include reduced exacerbations and need for immunoglobulin.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Bias Reduction, Better Access Key to COVID-19 Equity Gains
April 14th 2025Interventions that target enhancing health care equity among communities disproportionately affected by the COVID-19 pandemic can be improved by including comprehensive needs assessments at the patient, provider, and health system levels.
Read More
Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.
Read More